vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and PAMT CORP (PAMT). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $141.3M, roughly 1.3× PAMT CORP). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -20.7%, a 34.0% gap on every dollar of revenue. On growth, Amphastar Pharmaceuticals, Inc. posted the faster year-over-year revenue change (-1.8% vs -15.1%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $-25.0M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -12.0%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
AMPH vs PAMT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $141.3M |
| Net Profit | $24.4M | $-29.3M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | -27.0% |
| Net Margin | 13.3% | -20.7% |
| Revenue YoY | -1.8% | -15.1% |
| Net Profit YoY | -35.7% | 7.4% |
| EPS (diluted) | $0.51 | $-1.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $141.3M | ||
| Q3 25 | $191.8M | $150.3M | ||
| Q2 25 | $174.4M | $151.1M | ||
| Q1 25 | $170.5M | $155.3M | ||
| Q4 24 | $186.5M | $166.5M | ||
| Q3 24 | $191.2M | $182.6M | ||
| Q2 24 | $182.4M | $182.9M | ||
| Q1 24 | $171.8M | $182.6M |
| Q4 25 | $24.4M | $-29.3M | ||
| Q3 25 | $17.4M | $-5.6M | ||
| Q2 25 | $31.0M | $-9.6M | ||
| Q1 25 | $25.3M | $-8.1M | ||
| Q4 24 | $38.0M | $-31.6M | ||
| Q3 24 | $40.4M | $2.4M | ||
| Q2 24 | $37.9M | $-2.9M | ||
| Q1 24 | $43.2M | $281.0K |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | -27.0% | ||
| Q3 25 | 13.2% | -3.8% | ||
| Q2 25 | 24.2% | -7.3% | ||
| Q1 25 | 21.9% | -5.9% | ||
| Q4 24 | 24.2% | -22.6% | ||
| Q3 24 | 29.8% | 1.3% | ||
| Q2 24 | 30.3% | -0.4% | ||
| Q1 24 | 27.9% | -0.4% |
| Q4 25 | 13.3% | -20.7% | ||
| Q3 25 | 9.0% | -3.7% | ||
| Q2 25 | 17.8% | -6.4% | ||
| Q1 25 | 14.8% | -5.2% | ||
| Q4 24 | 20.4% | -19.0% | ||
| Q3 24 | 21.1% | 1.3% | ||
| Q2 24 | 20.8% | -1.6% | ||
| Q1 24 | 25.1% | 0.2% |
| Q4 25 | $0.51 | $-1.38 | ||
| Q3 25 | $0.37 | $-0.27 | ||
| Q2 25 | $0.64 | $-0.46 | ||
| Q1 25 | $0.51 | $-0.37 | ||
| Q4 24 | $0.74 | $-1.44 | ||
| Q3 24 | $0.78 | $0.11 | ||
| Q2 24 | $0.73 | $-0.13 | ||
| Q1 24 | $0.81 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $83.7M |
| Total DebtLower is stronger | $608.7M | $333.9M |
| Stockholders' EquityBook value | $788.8M | $210.5M |
| Total Assets | $1.6B | $697.9M |
| Debt / EquityLower = less leverage | 0.77× | 1.59× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $83.7M | ||
| Q3 25 | $276.2M | $115.6M | ||
| Q2 25 | $231.8M | $117.3M | ||
| Q1 25 | $236.9M | $102.7M | ||
| Q4 24 | $221.6M | $110.7M | ||
| Q3 24 | $250.5M | $92.3M | ||
| Q2 24 | $217.8M | $114.0M | ||
| Q1 24 | $289.6M | $125.8M |
| Q4 25 | $608.7M | $333.9M | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | $325.6M | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $210.5M | ||
| Q3 25 | $776.7M | $239.5M | ||
| Q2 25 | $757.5M | $244.9M | ||
| Q1 25 | $751.3M | $269.6M | ||
| Q4 24 | $732.3M | $277.5M | ||
| Q3 24 | $727.7M | $308.9M | ||
| Q2 24 | $713.3M | $306.7M | ||
| Q1 24 | $672.4M | $314.6M |
| Q4 25 | $1.6B | $697.9M | ||
| Q3 25 | $1.7B | $715.2M | ||
| Q2 25 | $1.6B | $707.9M | ||
| Q1 25 | $1.6B | $712.6M | ||
| Q4 24 | $1.6B | $741.7M | ||
| Q3 24 | $1.5B | $756.7M | ||
| Q2 24 | $1.5B | $733.5M | ||
| Q1 24 | $1.6B | $746.4M |
| Q4 25 | 0.77× | 1.59× | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | 1.17× | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $-5.8M |
| Free Cash FlowOCF − Capex | $24.6M | $-25.0M |
| FCF MarginFCF / Revenue | 13.4% | -17.7% |
| Capex IntensityCapex / Revenue | 4.5% | 13.6% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $-23.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $-5.8M | ||
| Q3 25 | $52.6M | $5.9M | ||
| Q2 25 | $35.6M | $12.2M | ||
| Q1 25 | $35.1M | $5.0M | ||
| Q4 24 | $29.0M | $15.2M | ||
| Q3 24 | $60.0M | $15.5M | ||
| Q2 24 | $69.1M | $18.7M | ||
| Q1 24 | $55.3M | $9.6M |
| Q4 25 | $24.6M | $-25.0M | ||
| Q3 25 | $47.2M | $2.5M | ||
| Q2 25 | $25.0M | $5.9M | ||
| Q1 25 | $24.4M | $-6.8M | ||
| Q4 24 | $16.6M | $-39.9M | ||
| Q3 24 | $46.2M | $-33.6M | ||
| Q2 24 | $63.1M | $4.1M | ||
| Q1 24 | $46.5M | $-12.2M |
| Q4 25 | 13.4% | -17.7% | ||
| Q3 25 | 24.6% | 1.7% | ||
| Q2 25 | 14.3% | 3.9% | ||
| Q1 25 | 14.3% | -4.4% | ||
| Q4 24 | 8.9% | -24.0% | ||
| Q3 24 | 24.1% | -18.4% | ||
| Q2 24 | 34.6% | 2.2% | ||
| Q1 24 | 27.1% | -6.7% |
| Q4 25 | 4.5% | 13.6% | ||
| Q3 25 | 2.8% | 2.3% | ||
| Q2 25 | 6.1% | 4.2% | ||
| Q1 25 | 6.3% | 7.6% | ||
| Q4 24 | 6.7% | 33.1% | ||
| Q3 24 | 7.2% | 26.9% | ||
| Q2 24 | 3.3% | 8.0% | ||
| Q1 24 | 5.1% | 12.0% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | 6.44× | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | 34.11× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PAMT
| Freight Transportation Service | $123.1M | 87% |
| Fuel Surcharge | $18.2M | 13% |
